Vertex Pharmaceuticals (VRTX) Inventory (2011 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Inventory of $1.8 billion for Q1 2026, up 29.93% year-over-year from $1.4 billion in Q1 2025, and up 4.74% quarter-over-quarter from $1.7 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Inventory (2011 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Inventory history runs 16 years deep, the most recent figure standing at $1.8 billion for Q1 2026.
- In Q1 2026, Inventory rose 29.93% year-over-year to $1.8 billion; the TTM figure through Mar 2026 stood at $1.8 billion (up 29.93% YoY), while the FY2025 annual figure was $1.7 billion, up 39.94% from the prior year.
- Inventory for Q1 2026 stood at $1.8 billion, up from $1.7 billion in the prior quarter.
- The five-year high for Inventory was $1.8 billion in Q1 2026, with the low at $338.9 million in Q1 2022.
- The 5-year median for Inventory is $813.1 million (2024), against an average of $945.5 million.
- The sharpest annual moves came in 2022 and 2023: Inventory rose 13.4% in 2022, then surged 77.41% in 2023.
- Vertex Pharmaceuticals' Inventory stood at $460.6 million in 2022, then jumped by 60.4% to $738.8 million in 2023, then surged by 63.16% to $1.2 billion in 2024, then soared by 39.94% to $1.7 billion in 2025, then gained by 4.74% to $1.8 billion in 2026.
- Business Quant data shows VRTX's Inventory at $1.8 billion in Q1 2026, $1.7 billion in Q4 2025, and $1.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.77 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.08 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 371.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 732.60 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 358,916.96 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 97.11 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 142.38 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.77 Bn |
| Mar 31, 2026 | 1.77 Bn |
| Dec 31, 2025 | 1.69 Bn |
| Sep 30, 2025 | 1.63 Bn |
| Jun 30, 2025 | 1.50 Bn |
| Mar 31, 2025 | 1.36 Bn |
| Dec 31, 2024 | 1.21 Bn |
| Sep 30, 2024 | 1.08 Bn |
| Jun 30, 2024 | 914.60 Mn |
| Mar 31, 2024 | 813.10 Mn |
| Dec 31, 2023 | 738.80 Mn |
| Sep 30, 2023 | 688.70 Mn |
| Jun 30, 2023 | 603.50 Mn |
| Mar 31, 2023 | 535.10 Mn |
| Dec 31, 2022 | 460.60 Mn |
| Sep 30, 2022 | 388.20 Mn |
| Jun 30, 2022 | 367.70 Mn |
| Mar 31, 2022 | 338.90 Mn |
| Dec 31, 2021 | 353.10 Mn |
| Sep 30, 2021 | 333.46 Mn |